AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04784325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood draw through standard venipuncture
Description: One phlebotomist-performed standard venipuncture
Study NCT06567145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Enhancement Cognitive Therapy (NECT)
Description: The Narrative Enhancement and Cognitive Therapy (NECT) consists of 20 group sessions divided into five parts: orientation (2 sessions), psychoeducation on stigma (3 sessions), cognitive restructuring (7 sessions), narrative enhancement (7 sessions), and a concluding reflection (1 session). The program helps participants challenge self-stigmatizing beliefs, develop coping skills, and create a new, positive narrative about themselves. Each session lasts about an hour, with a structured format of introduction, main discussion, and conclusion, encouraging active participation and reflection on personal experiences. The intervention ultimately fosters self-efficacy, control, and hope for the future.
Study NCT04944277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ThoughtFullChat Application
Description: A subscription-based mobile platform that empowers users to proactively engage with their mental health via self-serve tools and 1-on-1 daily bite-sized coaching with certified mental health professionals.
Study NCT04592042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feel-Good- Group
Description: Eight sessions of group intervention focussing on information on emotion regulation, training of emotion regulation techniques and mindfulness.
Study NCT05564416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT05564416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05564416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT05852119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient treatment with standard anticoagulant therapy
Description: All patients included in the study will be treated on an outpatient basis, that is, they will be discharged within the first 24 hours of the diagnosis of PE in the Emergency Department.
Study NCT05889104 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Randomization Program
Description: The subjects in the Control Group will undergo twelve weeks of low impact Aerobics Training along with a health awareness program
Study NCT05889104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Loading Protocol (PLP):
Description: he subjects in the Progressive Loading Group will undergo 4-7 days of moderate to high impact loading activities per week.
Study NCT05225038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will meet with an exercise physiologist to undergo evaluation and develop individualized regimens for prehabilitation.
Study NCT05225038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional
Description: Participants will meet with a nutritionist to undergo evaluation and develop individualized regimens for prehabilitation.
Study NCT05225038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Medicine
Description: Participants will have 1 appointment with behavioral medicine - all participants will meet with the same behavioral medicine specialist to ensure consistency. Participants will receive education regarding factors that affect postoperative recovery and relaxation techniques.~Participants will also have the option to request faith support.
Study NCT05225038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Medicine
Description: Participants will have 1 appointment with behavioral medicine - all participants will meet with the same behavioral medicine specialist to ensure consistency. Participants will receive education regarding factors that affect postoperative recovery and relaxation techniques.~Participants will also have the option to request faith support.
Study NCT05225038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: Participants who are actively smoking will be counseled regarding smoking cessation during their preoperative appointment with a member of the surgical team. They will also be offered a referral to smoking cessation resources.
Study NCT05225038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation
Description: Participants who are actively smoking will be counseled regarding smoking cessation during their preoperative appointment with a member of the surgical team. They will also be offered a referral to smoking cessation resources.
Study NCT05556473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-(2-[18F]FLUOROETHYL)-L-Tryptophan
Description: Radioactive tracer 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan 0.14mCi/kg/5MBq/kg injection given one time prior to PET Scan.
Study NCT04989751 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: Electromyography (EMG) would be used at the baseline for dignoisis and furtue analysis.
Study NCT04989751 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IDEAL MRI
Description: Muscle-speciifc sequences (e.g. IDEAL) would be used to scan patients at baseline and follow-up stages to characterize the fat fraction and atrophy in different muscles.
Study NCT04777851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib in combination with pembrolizumab
Description: Randomized patients will receive regorafenib at a dose of 90 mg per day by mouth on days 1 to 21 of a 28-day cycle, in combination with pembrolizumab 400 mg using a 30-minute intravenous infusion, on day 1 (D1) of a 6-week cycle.
Study NCT04777851 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Loco-regional therapy
Description: Patients will be treated with TACE or TARE on-demand according to site's standard of practice.
Study NCT05879185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb23104
Description: XmAb23104 (10 mg/kg) intravenously on days 1 and 15 of each 28-day cycle. XmAb23104 will be administered by IV infusion at a constant rate over 1 hour.
Study NCT05564416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05564416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Description: Undergo cystoscopy
Study NCT05564416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given PO
Study NCT05358236 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Episiotomy Wound Care and Genital Hygiene Training
Description: Episiotomy wound healing and genital hygiene training were given face-to-face by researchers to the mothers assigned to the training group. The trainings were given to each mother individually in their rooms. The total training lasted an average of one hour. At the end of the training, the mothers were given a written and illustrated training brochure.~Training content~* Primarily, external reproductive organs were shown to mothers through pictures.~* Urethra, Vagina, Anus, Perineum areas were mentioned.~* The definition of Episiotomy was made; and where and how it was applied was explained with visual materials. It was explained how to care for the episiotomy area to heal more rapid and healthier.~* Information was given on how to change their menstrual pads.~* Information was provided on what to look for when using underwear~* What to watch out while taking a bath:~* What to pay attention to in your stitch area
Study NCT05985954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given by IV (vein)
Study NCT05985954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: Given by PO
Study NCT05985954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given by PO
Study NCT05564416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06442033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity stationary cycling
Description: All community based exercise sessions are: 3x/week for 40 min, which includes a 5-min warm up \& cool down and a 30-minute main exercise set. Exercise parameters will be set by a neurologically trained physical therapist and will be progressed over time with the ultimate goal of the individual reaching moderate-vigorous exercise. Moderate-vigorous exercise for this project is defined as a cadence of 75+ rpms and a target HR of 60-80% of their age-predicted max
Study NCT05841186 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Timing of pegfilgrastim administration
Description: Timing of pegfilgrastim administration
Study NCT05829694 — intervention group
Intervention type: OTHER
Intervention: Parental Status
Description: The aim of the study is to assess the impact parenthood has on health outcomes.
Study NCT06409533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rate control
Description: Patients diagnosed with atrial fibrillation due to moderate to severe rheumatic mitral stenosis (AF-RMS) and undergoing treatment will receive care in accordance with the PERKI (Indonesian Heart Association) guidelines for Atrial Fibrillation. The selection and titration of rate control medications, including β-blockers, digoxin, or their combination, will be managed by the attending cardiologists (care providers) to achieve the target rate control.
Study NCT06409533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rate control
Description: Patients diagnosed with atrial fibrillation due to moderate to severe rheumatic mitral stenosis (AF-RMS) and undergoing treatment will receive care in accordance with the PERKI (Indonesian Heart Association) guidelines for Atrial Fibrillation. The selection and titration of rate control medications, including β-blockers, digoxin, or their combination, will be managed by the attending cardiologists (care providers) to achieve the target rate control.
Study NCT05141019 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Panel-based pharmacogenetic genotyping
Description: After providing consent, subjects will be randomized to receive either the immediate pharmacogenetic testing arm or the delayed arm. Subjects in both groups will provide a DNA sample by saliva, buccal cell, or blood at study enrollment. Subjects assigned to the immediate pharmacogenetic genotyping group will be tested and will have their results entered into their electronic health record (EHR) and provided to them within 2-4 weeks. Subjects assigned to the delayed pharmacogenetic genotyping group will also be tested, but their results will not be released until after their participation in the study has ended. Subjects in each arm will complete surveys and questionnaires regarding their medication satisfaction, as well as their healthcare utilization use at baseline and then again at 6- and 12-months. Implementation-specific questions will also be asked to assess the feasibility and sustainability of the intervention as well as assessments of intervention fidelity and adaptations.
Study NCT05141019 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Panel-based pharmacogenetic genotyping
Description: After providing consent, subjects will be randomized to receive either the immediate pharmacogenetic testing arm or the delayed arm. Subjects in both groups will provide a DNA sample by saliva, buccal cell, or blood at study enrollment. Subjects assigned to the immediate pharmacogenetic genotyping group will be tested and will have their results entered into their electronic health record (EHR) and provided to them within 2-4 weeks. Subjects assigned to the delayed pharmacogenetic genotyping group will also be tested, but their results will not be released until after their participation in the study has ended. Subjects in each arm will complete surveys and questionnaires regarding their medication satisfaction, as well as their healthcare utilization use at baseline and then again at 6- and 12-months. Implementation-specific questions will also be asked to assess the feasibility and sustainability of the intervention as well as assessments of intervention fidelity and adaptations.
Study NCT06467825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Supplement
Description: Participants will be given a potassium supplement that will help prevent low blood potassium levels.
Study NCT06467825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 20 MG
Description: Furosemide (Lasix, 20 mg) will be administered through IV catheter to induce urination. The goal of this procedure is to reduce the volume of plasma in the blood.
Study NCT06467825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression Garment
Description: From the torso and leg measurements obtained during Visit 1A, a custom-designed compression garment will be constructed.
Study NCT05933941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: This is a game set in space in which you pilot a spaceship and have to go through rings while dodging meteorites, all controlled by neck movements. Before starting the game, the assigned therapist is in charge of establishing the necessary movement parameters. In addition, the software allows you to modify the difficulty of the game. We will start the first 3 sessions in easy mode, where cervical mobility does not exceed 30º. The following 3 sessions will be configured in medium mode, reaching 60º of mobility. In the last 2 sessions, we will select the hard mode, which not only increases the speed of the spacecraft but also covers the entire range of cervical mobility.
Study NCT05933941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: The patients perform mobility and strengthening exercises for the cervical region, in which they are required to complete 1 set of 10 repetitions for each exercise. The patient should rest for at least 30 seconds between exercises.
Study NCT06379659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growh hormone
Description: In this group, patients will receive growth hormone solution containing 1.99 milligrams of the drug dissolved in 1.5 milliliters of 0.9% saline solution (normal saline), in addition to standard hormonal therapy, starting from cycle day 10. Treatment sessions will be conducted at two-day intervals. In case of non-response to treatment (failure to reach a minimum endometrial thickness of 7 millimeters in the subsequent assessment), the patient will receive a maximum of 4 doses, and if response to treatment is observed, growth hormone infusion will be discontinued. All infusions will be administered intrauterinely via an Intrauterine Insemination (IUI) catheter.
Study NCT06379659 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar to the intervention group, from cycle day 10, an equal volume of 0.9% saline solution (normal saline) will be administered in addition to standard hormonal therapy. Treatment sessions will be conducted at two-day intervals. In case of non-response to treatment (failure to reach a minimum endometrial thickness of 7 millimeters in the subsequent assessment), the patient will receive a maximum of 4 doses, and if response to treatment is observed, placebo infusion will be discontinued. All infusions will be administered intrauterinely via an Intrauterine Insemination (IUI) catheter.
Study NCT06218277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ASTAR
Description: Rapid AST with ASTAR
Study NCT05442554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin IV infusion.
Study NCT06019754 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: one point combined Lumbar and sacral plexus block
Description: performing an ultrasound-guided one-point combined Lumbar and sacral plexus block using a one-point puncture. Block success will be assessed using the perfusion index (PI) before and after performing the block
Study NCT06019754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: one point combined Lumbar and sacral plexus block
Description: performing an ultrasound-guided one-point combined Lumbar and sacral plexus block using a one-point puncture. Block success will be assessed using the perfusion index (PI) before and after performing the block
Study NCT06371612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Parental Presence
Study NCT06371612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adhesive Remover Spray
Description: Parental Presence + an alcohol-free silicone-based aresol spray for medical use
Study NCT06371612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ball Squeezing + Adhesive Remover Spray
Description: Parental Presence + an alcohol-free silicone-based aresol spray for medical use + squeezing the stress ball
Study NCT06088992 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HG004
Description: Method of Administration: Once unilateralsubretinal injection; The duration of the study isabout 60 weeks for each subject including a 8-weekscreening period, enrollment/baseline visit,treatment visit, and 52 weeks follow-up period.
Study NCT06560489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.
Description: This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.
Study NCT06327945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung uDCD Protocol
Description: The intervention is initiation of PEEP and supplemental oxygen, without requiring prior permission (e.g., for cases not having first person authorization for organ donation and organ donation for research), to offer lung donation opportunities for cases which would otherwise be ineligible in the U.S.
Study NCT04769479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acoramidis
Description: acoramidis
Study NCT05371886 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dose-effect relationship of morphine +/- midazolam administration
Description: Dose-effect relationship of morphine +/- midazolam administration as continuous infusion in neonates undergoing mechanical ventilation through PKPD modelling
Study NCT05960097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0701 Bivalent High dose
Description: Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
Study NCT05960097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0701 Bivalent Medium dose
Description: Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
Study NCT05960097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0701 Bivalent Low dose
Description: Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
Study NCT05960097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0601 Monovalent High dose
Description: Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
Study NCT05960097 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control vaccine
Description: Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
Study NCT05960097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0801 Monovalent
Description: Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
Study NCT05614531 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: EXG001-307 injection
Description: non-replicating, rAAV vector based on AAV9 containing cDNA encoding the human SMN protein.
Study NCT05135702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Propionate
Description: a 500 mg powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.
Study NCT05135702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium Propionate
Description: a 500 mg powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.
Study NCT05135702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a color, size, calorie, and consistency-matched powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.
Study NCT05135702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: a color, size, calorie, and consistency-matched powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.
Study NCT04689139 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sample tests for determination of biomarkers levels
Description: Using of proadrenomedullin, presepsin, NT-proBNP, Troponin I to determine the correlation of perioperative complications.
Study NCT05464667 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Dose Escalation: 5 Cohorts - 30 GY in 5 fractions (baseline treatment with 0 boost dose to GTV), 35, 40, 45, 50 Gy in 5 fractions (Part 1)~Dose Expansion: Maximum Tolerated Dose determined during dose escalation (Part 2)
Study NCT05521607 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Picterus Jaundice Pro (JP)
Description: Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.